Business Description
Senhwa Biosciences Inc
ISIN : TW0006492002
Total Employee Number:
16Description
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 34.9 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 40.41 | |||||
Beneish M-Score | -2.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.9 | |||||
3-Year EBITDA Growth Rate | 9.7 | |||||
3-Year EPS without NRI Growth Rate | 8.8 | |||||
3-Year FCF Growth Rate | 14.7 | |||||
3-Year Book Growth Rate | -22.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.56 | |||||
9-Day RSI | 46.69 | |||||
14-Day RSI | 45.98 | |||||
3-1 Month Momentum % | -12.62 | |||||
6-1 Month Momentum % | -0.67 | |||||
12-1 Month Momentum % | 35.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.21 | |||||
Quick Ratio | 17.21 | |||||
Cash Ratio | 17.02 | |||||
Days Sales Outstanding | 31.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -0.08 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 48.6 | |||||
Operating Margin % | -26005.51 | |||||
Net Margin % | -24744.77 | |||||
EBITDA Margin % | -23418.22 | |||||
FCF Margin % | -23220.28 | |||||
OCF Margin % | -23220.28 | |||||
ROE % | -29.44 | |||||
ROA % | -28.17 | |||||
ROIC % | -628.42 | |||||
3-Year ROIIC % | 344.89 | |||||
ROC (Joel Greenblatt) % | -1227.55 | |||||
ROCE % | -28.83 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3361.54 | |||||
PB Ratio | 5.14 | |||||
Price-to-Tangible-Book | 5.14 | |||||
EV-to-EBIT | -12.02 | |||||
EV-to-EBITDA | -12.6 | |||||
EV-to-Revenue | 2949.99 | |||||
EV-to-FCF | -12.96 | |||||
Price-to-GF-Value | 0.93 | |||||
| Price-to-Net-Current-Asset-Value | 5.41 | |||||
| Price-to-Net-Cash | 5.48 | |||||
Earnings Yield (Greenblatt) % | -8.32 | |||||
FCF Yield % | -6.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Senhwa Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1.07 | ||
| EPS (TTM) (NT$) | -2.97 | ||
| Beta | 0.061 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 47 | ||
| 14-Day RSI | 45.98 | ||
| 14-Day ATR (NT$) | 1.231893 | ||
| 20-Day SMA (NT$) | 43.6 | ||
| 12-1 Month Momentum % | 35.68 | ||
| 52-Week Range (NT$) | 32.75 - 66.5 | ||
| Shares Outstanding (Mil) | 89.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Senhwa Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Senhwa Biosciences Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| 0.47733:1 Stock Split | 2020-03-16 | 56.27 (+3.60%) |
Show
Entries
Senhwa Biosciences Inc Frequently Asked Questions
What is Senhwa Biosciences Inc(ROCO:6492)'s stock price today?
The current price of ROCO:6492 is NT$43.70. The 52 week high of ROCO:6492 is NT$66.50 and 52 week low is NT$32.75.
When is next earnings date of Senhwa Biosciences Inc(ROCO:6492)?
The next earnings date of Senhwa Biosciences Inc(ROCO:6492) is .
Does Senhwa Biosciences Inc(ROCO:6492) pay dividends? If so, how much?
Senhwa Biosciences Inc(ROCO:6492) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Senhwa Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers